Notable 52-Week Highs and Lows 8/10: (YELP) (REN) (HWAY) High; (SPWR) (MYGN) (MCHX) Low
- Wall St opens higher as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q
August 11, 2016 8:37 AM EDTJefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More
Needham & Company Raises Price Target on Yirendai (YRD) Following Strong 2Q
August 11, 2016 7:05 AM EDTNeedham & Company reiterated a Buy rating on Yirendai Ltd. (NYSE: YRD), and raised the price target to $35.00 (from $14.00), following the company's 2Q earnings report. Revenue of $110.4 million was up 29.8% Q/Q and and 140% Y/Y, ahead of $97.0 million estimates. The company reported $0.67 in Non-GAAP EPS,... More